Huoxiang Zhengqi oral liquid for prevention of cisplatin-induced CINV

Phase 4, randomised, double-blind trial of Huoxiang Zhengqi in chemotherapy-induced nausea and vomiting (CINV) (2 arms), sponsored by West China Hospital of Sichuan University. Primary endpoints: Average number of nausea and vomiting-free days (NCDs) throughout the entire cycle and Complete control rate of CINV outside of the risk phase. Planned start Mar 2023; status: not yet recruiting.